NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines that can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease.

Pharmaceutical

NeuBase Therapeutics

Dietrich A. Stephan

Nathan T.

Lindsey Spiker

Steven Murphy

Kayla Williams

Chelsea Martinez

Barry Badeau

William Riedl

Lydia(Lyuqin) Chen

Jeremy Gleaton

Sally Edmonds

Ranajoy Sarkar

Jonathan Leung

John J. Thomas

Dov Goldstein

Jessica Balogh

Eric Richman

Todd P. Branning

Sandra Rojas-Caro

The executive team at NeuBase Therapeutics has a history of working in the biopharmaceutical industry and in corporate development. They have experience with Lodestar Biopharma Solutions LLC, Helsinn Therapeutics (U.S.), Inc., Sapphire Therapeutics, Inc., and Novartis. They also have education histories from The Rockefeller University and the University of Aberdeen in human genetics and biochemistry, respectively.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Team members

Other teams at NeuBase Therapeutics

Board of Directors

Leadership Team